TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03515499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication device monitoring and reminders
Description: Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
Study: NCT03263416

Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up
Description: - Completion of QLQ-C30 and GIRERD questionnaires
Study: NCT05264194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suturing technique
Description: The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suturing technique
Description: The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
Study: NCT04738916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Description: Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
Study: NCT02818777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties.
Study: NCT02325011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® (Treatment A)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® (Treatment A)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® and fluconazole concomitantly (Treatment B)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose.
Study: NCT00895310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole is taken three times a day by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
Study: NCT00411814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK679586
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00240500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
Study: NCT01315444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stop PPI gradually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stop PPI gradually
Study: NCT01025830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triomune
Description: Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zerit/Epivir/Viramune
Description: Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
Study: NCT03642730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransThoracic Echocardiography imaging
Description: ultrasound scanning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransThoracic Echocardiography imaging
Description: ultrasound scanning
Study: NCT02493075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The operator blinded to the contact force data or not.
Description: CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The operator blinded to the contact force data or not.
Description: CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I.
Study: NCT03236987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 1000 MG
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg
Description: The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
Study: NCT04209933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study: NCT02325011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex® and fluconazole concomitantly (Treatment B)
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose.
Study: NCT01848132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: oral, 100 mg, days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone: oral, 100 mg, days 1-5
Study: NCT03733704

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate variability analysis
Description: Heart rate variability analysis extracted from ECG during normal and obstructed breathing
Study: NCT03927703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically once daily
Study: NCT06481046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
Study: NCT03955211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 300 mg
Study: NCT04209933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth capsules containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth capsules containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth capsules containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth capsules containing quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth capsules 200 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles A quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study: NCT03955211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock Applicator
Description: Applicator for instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 975 mg to 1 g
Study: NCT04613687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression bandage
Description: Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
Study: NCT03104686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short pasta (dry)
Description: 50g available carbohydrate of penne pasta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long pasta (dry)
Description: 50g available carbohydrate of spaghetti pasta

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: 50g available carbohydrate of bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50g available carbohydrate of glucose monohydrate
Study: NCT01091116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.125 mg
Description: Intra-articular administration of two low doses of MEN16132 at 2-week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.25 mg
Description: Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
Study: NCT04209933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles A quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles A quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles A quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 150 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles B quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal pectin bismuth particles B quadruple therapy
Description: Bismuth potassium citrate:given for 14 days at a dose of Colloidal pectin bismuth particles 300 mg BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID
Study: NCT01091116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.5 mg
Description: Intra-articular injection of two high doses of MEN16132 at 2-week interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN16132 - 0.5 mg
Description: Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection of 2 doses of Placebo control at 2-week interval
Study: NCT02050256

Intervention type: OTHER
Group type: OTHER
Intervention: continuing medical education and electronic decision support
Study: NCT02820012

Intervention type: OTHER
Group type: OTHER
Intervention: Scoliosis
Description: Questionnaires, radiography
Study: NCT04437966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Chronic Disease Self-management program
Description: CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
Study: NCT02459028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology intervention
Description: Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychology intervention (Control exercise)
Description: Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
Study: NCT02897674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm olein
Description: two thirds of the 30% fat calories will come from palm olein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm olein
Description: two thirds of the 30% fat calories will come from palm olein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein
Description: two thirds of the 30% fat calories will come from interesterified palm olein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein
Description: two thirds of the 30% fat calories will come from interesterified palm olein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soybean oil
Description: two thirds of the 30% fat calories will come from soybean oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soybean oil
Description: two thirds of the 30% fat calories will come from soybean oil
Study: NCT00433563

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Once daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Once daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
Study: NCT02050256

Intervention type: OTHER
Group type: OTHER
Intervention: education and electronic support
Description: Continuing medical education and electronic decision support to General Practitioners.
Study: NCT02715115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution and Water for Injection
Study: NCT03852732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study: NCT01949402

Intervention type: OTHER
Intervention: Computed Tomography
Description: The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit.
Study: NCT02058966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entacapone
Description: Entacapone 200 mg oral dose